Atlas Trials

A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma

Clinical trial NCT06083207 · RECRUITING

Trial details

NCT number
NCT06083207
Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Status
RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Multiple Myeloma
Start date
2024-07-29
Primary completion
2026-10-31
Enrollment
116

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.